An innovative genetic study of blood protein levels, led by researchers in the MRC Integrative Epidemiology Unit (MRC-IEU) at the University of Bristol, has demonstrated how genetic data can be used to support drug target prioritisation by identifying the causal effects of proteins on diseases.
There are encouraging signs that people in treatment for drug addiction can manage their medication when they are entrusted with a substantial quantity of opiate substitutes and told to take it in small daily doses, finds a new ‘early insight’ report from researchers at the Universities of Bristol and Bath.
Major reallocation of healthcare services during the COVID-19 pandemic meant that elective surgery in children with congenital heart disease (CHD) was significantly reduced, so that those needing urgent, lifesaving and emergency surgery could be treated. However, this prioritisation of the most severely ill children did not increase overall post-operative complications rates or death, a study led by the University of Bristol has shown.
The number of young people with anxiety doubled from 13 per cent to 24 per cent, during the early stages of the COVID-19 pandemic and lockdown 1, according to new research from the University of Bristol. The study, using Bristol’s Children of the 90s questionnaire data, showed that young people (27-29 years) reported higher levels of anxiety during the early phases of the pandemic in the first national lockdown and this was higher than their parents.
The proportion of adolescents living with overweight or obesity in England has increased by 50% from 2008-2010 (22%) to 2021-2023 (33%) according to two new studies involving University of Bristol researcher, Dr Dinesh Giri. The research is being presented at next month's [11-14 May] European Congress on Obesity (ECO).
Gastric bypass is the most clinically and cost effective form of interventional surgery for people living with severe obesity, reveals landmark research. The new University of Bristol-led trial, funded by the National Institute for Health and Care Research (NIHR), is published today [31 March] in The Lancet Diabetes & Endocrinology.
A study looking at how children's immune systems respond to COVID-19, and to vaccines for other infectious diseases, is asking children under the age of 20 who live in the Bristol area to consider taking part. The research project is being run by the Bristol Children’s Vaccine Centre (BCVC) at Bristol Medical School, and the Oxford Vaccine Group which is part of the University of Oxford.
The University of Bristol has secured a £45million deal to advance its groundbreaking gene therapy technology for chronic kidney diseases. The commitment, made by healthcare company Syncona Ltd to Bristol spin-out Purespring Therapeutics, aims to address a global unmet need for renal conditions in one of the largest single investments made to a new UK university biotech company.
Corticosteroids reduce the risk of death among critically ill COVID-19 patients by 20 per cent, an analysis of seven trials published today [2 September] in the Journal of the American Medical Association (JAMA) has found. The results of three of the trials included in the meta-analysis are also published in JAMA today.
A new genetic cause of neurodevelopmental disorder (NDD) has been uncovered by an international team of researchers. The discovery, published in Nature Genetics [10 Apr] and led by the University of Bristol, the Icahn School of Medicine at Mount Sinai in New York and KU Leven in Belgium, offers diagnostic certainty and hope to potentially thousands of families worldwide who have long been searching for answers.
